Apogee Therapeutics
APGE
Market cap $3.11B

54.88 USD

-0.93

1.67%

At close Oct 15, 4:00 PM EDT

1 day

-1.67%

5 days

-2.35%

1 month

6.56%

3 months

11.14%

6 months

3.41%

Year to date

92.49%

1 year

169.42%

5 years

158.50%

About: Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.

Employees: 91

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

15% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 41

1% more funds holding

Funds holding: 137 [Q1] → 139 (+2) [Q2]

6% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 33

0.29% less ownership

Funds ownership: 120.71% [Q1] → 120.42% (-0.29%) [Q2]

40% less capital invested

Capital invested by funds: $3.52B [Q1] → $2.13B (-$1.39B) [Q2]

64% less funds holding in top 10

Funds holding in top 10: 11 [Q1] → 4 (-7) [Q2]

87% less call options, than puts

Call options by funds: $87K | Put options by funds: $652K

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for APGE.

See Analyst Rankings

Financial journalist opinion

Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit

SAN FRANCISCO and WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that members of management, will participate in a fireside chat at the Stifel 2024 Immunology and Inflammation Summit on Wednesday, September 18, 2024 at 12:30 p.m. E.T. / 9:30 a.m. P.T.

Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit

Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer

SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease and other I&I indications, today announced the appointment of Jeff S. Hartness as Chief Commercial Officer. Mr. Hartness has an extensive track record in commercial and corporate leadership, bringing more than 25 years of experience in the biotech industry focused on product launches, market access strategy, pricing and policy.

Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2025 Initiation of the first clinical trial of APG777 and APG990 combination expected to commence in 2025 with the potential for greater efficacy in atopic dermatitis and across I&I diseases SAN FRANCISCO and WALTHAM, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that it has initiated dosing of healthy volunteers in its first clinical trial for APG990, a novel, subcutaneous (SQ) half-life extended monoclonal antibody targeting OX40L, which is being developed initially as a treatment for people living with AD.

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results

Continued advancement of pipeline and execution towards expected milestones, including APG777 16-week proof-of-concept data from the Phase 2 Part A trial in 2H 2025, APG808 interim Phase 1 data in 4Q 2024, and APG990 Phase 1 trial initiation in healthy volunteers accelerated to 3Q 2024

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results

Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play

Apogee Therapeutics stock has declined by 34% since a previous recommendation to buy, while the S&P 500 is up 7.7%. Apogee Therapeutics raised $420 million at $62/share, expanding their financial runway while advancing APG777 into Phase 2 trials. APG777, targeting atopic dermatitis and asthma, shows promise with less frequent dosing, aiming to compete with Sanofi's Dupixent.

Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play

Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD

SAN FRANCISCO and WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today announced that Lisa Bollinger, MD, has been appointed to the company's board of directors. Dr. Bollinger most recently served as Vice President, Regulatory Affairs, Global Regulatory Affairs and Clinical Safety (GRACS) at Merck, where she led the general medicine therapeutic area in regulatory affairs. Dr. Bollinger's over 30 years of experience in drug development, with deep regulatory experience gained both within the U.S. FDA and multinational biotechnology and pharmaceutical companies contributed to the Apogee board of directors' selection decision.

Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD

Apogee Therapeutics to Participate in Upcoming June Investor Conferences

SAN FRANCISCO and WALTHAM, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, COPD, asthma and other inflammatory and immunology indications, today announced that members of management will participate at the following upcoming investor conferences:

Apogee Therapeutics to Participate in Upcoming June Investor Conferences

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Interim clinical data from APG777 Phase 1 healthy volunteers study exceeded all trial objectives and achieved a half-life of approximately 75 days with a potentially best-in-class profile

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results

Initiated a Phase 2 clinical trial of APG777, a subcutaneous half-life extended monoclonal antibody targeting IL-13, in patients with moderate-to-severe atopic dermatitis, with 16-week proof-of-concept data from Part A of the trial expected in 2H 2025

Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results

Earnings Superstars: 3 Stocks Primed to Outperform This Quarter

Companies have generally managed to perform well against the consensus of earnings forecasts, with around 77% of S&P 500 firms reporting in Q1 considered earnings outperformers. That rate is higher than the normal rate of around 74% recorded in the first three months of a year, with earnings outperformers beating historical trends.

Earnings Superstars: 3 Stocks Primed to Outperform This Quarter

See News Rankings

Charts implemented using Lightweight Charts™